Idioti, hanno cercato di distruggere un drago col fuoco! Drago Vaia in fiamme DEVE rinascere gofund.me/2238ee8d

Finally out on Journal of Clinical Oncology the 10-Year update of the ShortHER trial: proud and honored to be part of this relevant work Maria Vittoria Dieci ascopubs.org/doi/full/10.12…

🧬Molecular heterogeneity of HER2+ early BC influences the pattern of metastatic relapse 🩻Potential implications for follow up and clinical trial design Check out our new JNCI paper 👇🏻 Università di Padova Aleix Prat #PrecisionOncology Gaia Griguolo Federica Miglietta IOV - Istituto Oncologico Veneto academic.oup.com/jnci/advance-a…

In HR+HER2- early breast cancer, high genomic risk tumors by OncotypeDX present higher levels of TILs (more than 10%) ! -> potential clinical implications? Great minioral presentation today by Federica Miglietta of our group at #ESMO23 ! #bcsm Maria Vittoria Dieci Università di Padova IOV - Istituto Oncologico Veneto

Domani 11/11-Congresso AIOM WE ARE NEXT–Le frontiere dell’oncologia: focus ADC Gli anticorpi monoclonali farmaco-coniugati come promettente opzione terapeutica. Con P. Pronzato, Carmine De Angelis Maria Vittoria Dieci Matteo Lambertini, MD PhD, Sara Lonardi Francesco. Iscrizioni: overgroup.eu/evento/we-are-…

Nuova tappa per Next Oncology - Supporting Oncology through Innovation. Un simposio "Le frontiere dell' oncologia: focus ADC" sulle opzioni terapeutiche basate su anticorpi monoclonali farmaco-coniugati. P. Pronzato Carmine De Angelis Maria Vittoria Dieci Matteo Lambertini, MD PhD Sara Lonardi Francesco

ERlow = ERneg BC from molecular and immune perspective. Come to visit our poster P01-03-09. Find us in the “Triple Negative” poster row: a sign that times are finally mature for a change? Gaia Griguolo Federica Miglietta Università di Padova IOV - Istituto Oncologico Veneto #SABCS23 OncoAlert

What does it mean being married with an artist 👨🏻‍🎨👇🏻#illustration #comics #art #animation instagram marcomaselli_art

What does it mean being married with an artist. Part 2. Trailer “4:04”short animation movie. #animation #illustration #comics #art instagram.com/reel/C1cYKH9N4…

I have been waiting for almost 40 years… #grilloparlante #vintagetoys #millenial #newchallenges

Thank you Lorenzo Gerratana for your vision! This was a highly interactive meeting, honoured to have contributed.

Excited to launch the first edition of B.I.T. an event totally dedicated to translational research in breast cancer!! Join me and a stellar international faculty in Padova, 29-30th april. delphiecm.it/evento/b-i-t-b…

A lot of discussion these days around ER-low. We present data in >1200 MBC including prognosis, switch from primary tumor, TILs and data from the TONIC trial! Stop at poster board 78! #ASCO24 Federica Miglietta MarleenKokLab

Check Poster 558 #ASCO24 ! - PAM 50 and TILs/immune signatures capture only partially overlapping information on HR+/HER 2 BC biology Are pts with Basal-like HR+/HER 2 BC and high TILs r ideal candidates for neoadjuvant ICI+chemo? #bcsm Maria Vittoria Dieci OncoAlert TILs Working Group

Dr. Claudio Vernieri presents PALMARES2 study of head-head real-world comparison 3 CDK4/6i #BCSM #ASCO24 - N, 1850 - Abema&Ribo > Palbo in endocrine-resistent, luminal B, and liver mets - Abema > Palbo&Ribo in de novo MBC - Abema=Ribo=Palbo in older pts and bone-only dz

❓ How can gene expression assays guide the choice of adjuvant endocrine therapy in #breastcancer? 👉🏻 Check out our review in Clinical Cancer Research Gaia Griguolo Maria Vittoria Dieci Federica Miglietta aacrjournals.org/clincancerres/…